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A spectrum of lung diseases that affect the airways, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, primary ciliary dyskinesia, and non–cystic fibrosis bronchiectasis, can be character-
ized as muco-obstructive diseases.1-4 These diseases have the clinical features of 
cough, sputum production, and episodic exacerbations that are often associated 
with a diagnosis of chronic bronchitis.5 However, neither “chronic bronchitis” nor 
“hypersecretory diseases”6 adequately describes the diffuse mucus obstruction, 
airway-wall ectasia, chronic inflammation, and bacterial infection that are typical 
of these conditions; therefore, “muco-obstructive” may be a preferred descriptive 
term. Although asthma can also be associated with diffuse airway mucus obstruc-
tion,7 its distinct pathophysiological mechanisms preclude discussion in this 
grouping.8
The pathogenesis of muco-obstruction of the airways is depicted in Figure 1A. 
In healthy persons, a well-hydrated mucus layer is transported rapidly (at a rate of 
approximately 50 μm per second) from the distal airways toward the trachea. In 
muco-obstructive diseases, epithelial defects in ion–fluid transport, mucin secre-
tion, or a combination of these lead to hyperconcentrated (dehydrated) mucus, 
failed mucus transport, and mucus adhesion to airway surfaces. Mucus that is 
accumulated in the trachea can be expectorated by cough as phlegm or sputum.11 
Mucus in the small airways cannot be cleared by cough and accumulates, forming 
the nidus for airflow obstruction, infection, and inflammation.11
Bio chemic a l a nd Bioph ysic a l Properties of Mucus 
R el ati v e t o A irwa y Func tion
Human airway mucus is a hydrogel composed of approximately 98% water, 0.9% 
salt, 0.8% globular proteins, and 0.3% high-molecular-weight mucin polymers.12 
The hydration (concentration) status of mucus is measured as the wet-to-dry con-
tent of mucus (i.e., the percentage of a given volume that consists of nonvolatile 
solids) or as the mucin concentration determined by light-scattering tech-
niques.9,11,13 The correlation between the two measurements (in healthy persons or 
those with muco-obstructive disease) is high, which allows both measures to be 
used to describe this mucus property.9
The two major synthesized and secreted respiratory mucins, MUC5B and 
MUC5AC, are physically very large, spanning 0.2 to 10 μm in length for single 
polymers. The secreted mucin polymers interweave to form mesh-like gels with 
mesh sizes that are concentration dependent (i.e., higher concentrations are associ-
ated with smaller mesh sizes). MUC5B and MUC5AC share many features, includ-
ing their multimeric organization and high carbohydrate content (approximate-
ly 75% of total weight) (Fig. 1B).14 There are, however, major differences in the 
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regulation of transcription and probably the 
function of MUC5B and MUC5AC. Data from 
studies in mice indicate that Muc5b is required 
for basal mucociliary transport, whereas Muc5ac 
reacts to external stresses, features that are 
likely to be mimicked in humans. Recent data 
indicate that MUC5B is by concentration the 
dominant mucin (10:1 over MUC5AC) in normal 
human lower airways.10
The physical properties of mucus can be pre-
dicted from polymer physics15 that describe not 
only well-studied mucus viscoelastic properties 
but also other key biophysical properties, includ-
ing mucus osmotic pressure, adhesion, cohesion, 
and friction.11,13,15 The viscoelastic and osmotic 
properties of mucus, as with other polymer gels, 
scale to the third power, or higher, of concentra-
tion. This feature of mucus accounts for the 
observation that relatively small changes in con-
centration have profound effects on the bio-
physical and transport properties of mucus — 
for example, higher concentrations dramatically 
decrease transportability.13,16 In addition, the 
properties of mucus gels can be modified by 
conditions that create inter-mucin polymer in-
teractions with relatively long bond half-lives, 
producing “sticky” polymer gels whose viscous 
properties can scale to the eighth power of con-
centration.13,15
Mucin Concen tr ations in Muco -
Obs truc ti v e Lung Dise a ses
Mucin concentrations are abnormally raised in 
each of the four muco-obstructive diseases — 
COPD, cystic fibrosis, primary ciliary dyskinesia, 
and non–cystic fibrosis bronchiectasis — and 
these findings are consistent with a role for ele-
vated mucin concentrations in the pathogenesis 
of muco-obstructive disease (Fig. 1C). Although 
MUC5AC levels are elevated and may uniquely 
modify mucus properties, MUC5B is the domi-
nant mucin by concentration in these diseases.10
In tegr ated Cili a a nd Cough-
Dependen t Mucus Cle a r a nce
The classic views of the mucus transport system 
have undergone substantial revision at both 
macroscopic and microscopic length scales dur-
ing the past decade.13,17
Macroscopic — Intrapulmonary Mucin 
Sources
Mucus lines all airway surfaces as it moves to-
ward the throat through ciliary activity. Tradi-
Figure 1 (facing page). Muco-Obstructive Disease 
Pathogenesis, Mucin Species, and Total Mucin 
 Concentrations in Health and Disease.
Panel A shows the progression from normal to muco-
obstructed airways. In healthy persons (left), well- 
balanced epithelial sodium (Na+) absorption and secre-
tion of chloride anions (Cl−) hydrates airway surfaces 
and promotes efficient mucociliary clearance (MCC). 
In persons with muco-obstructive lung disease (middle), 
an imbalance of ion transport coupled with mucin hyper-
secretion increases mucin concentrations in the mucus 
layer, osmotically compresses the periciliary layer (PCL), 
and abolishes MCC. The adherent mucus may be ex-
pelled as sputum by cough (upper right). Mucus that 
cannot be expelled by cough accumulates, concentrates, 
obstructs airflow, and becomes the nidus for infection 
(lower right). CFTR denotes cystic fibrosis transmem-
brane conductance regulator, and ENaC the epithelial 
sodium channel. Panel B shows domain structures and 
relative sizes of the secreted mucins (MUC5AC and 
MUC5B) and tethered mucins (MUC1, MUC4, and 
MUC16). For reference, the globular protein albumin 
(ALB) is shown. The secreted mucins are composed of 
monomers with N terminals (MUC5AC, green; MUC5B, 
light blue), glycosylated domains, and C terminals 
(MUC5AC, yellow; MUC5B, purple). Both the C–C ter-
minal dimers and N–N terminal multimers are linked 
by S–S bonds. The glycosylated domains contain sugar 
side chains from 2 to 15 sugar molecules in length, often 
terminally capped with sialic acid or sulfate, which gives 
mucins a negative charge. The glycosylation domains 
provide mucin hydration, reflecting the avidity of sugar 
molecules for water, and a combinatorial library of bind-
ing sites capable of trapping most inhaled materials 
with a low but sufficient binding affinity to mediate 
clearance. The tethered mucins have cytoplasmic  
N-terminal (dark gray), transmembrane (light gray), 
and heavily glycosylated extracellular domains. For sim-
plicity, unique domains and proteolytic cleavage sites 
are not shown. Panel C shows total sputum mucin 
concentrations in healthy persons and patients with 
chronic obstructive pulmonary disease (COPD), non–
cystic fibrosis bronchiectasis (NCFB), cystic fibrosis 
(CF), or primary ciliary dyskinesia (PCD). Sputum mucin 
concentrations were measured by means of high-per-
formance liquid chromatography and refractometry.9,10 
T bars indicate standard errors of the mean.
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tionally, the superficial epithelia that line large 
(bronchial) and small (bronchiolar) airways were 
believed to secrete MUC5AC, whereas large-air-
way submucosal glands were thought to secrete 
MUC5B. Data from mouse models and human 
studies have led to a reformulation of this 
view.18,19 Under baseline conditions, the superfi-
cial epithelia of both human large and small 
airways secrete MUC5B. Airway MUC5B secre-
tion is supplemented by MUC5B secretion from 
the glands that may be in part tonic but probably 
can be greatly increased with cough.20 A variety 
of pulmonary stresses trigger superficial epithe-
lial MUC5AC expression.12 Recent research sug-
gests that MUC5AC secretion is superimposed 
on superficial airway secretory (club) cells that 
are competent for basal MUC5B secretion.18
Microscopic — Mucus Layer–Cilia Topography
The classic description of mucociliary clearance 
envisioned the movement of a mucus (gel) layer 
over a periciliary watery (liquid) layer, also called 
the “sol” layer.17 This description has been re-
placed by one depicting the mucociliary appara-
tus as comprising two gels: a mucus layer and a 
periciliary layer (Fig. 2A).13 The periciliary layer 
was identified as a dense gel composed of gly-
copolymers, including the MUC1, MUC4, and 
MUC16 mucins, tethered to epithelial-cell sur-
faces and cilia. An important concept that 
emerged from this formulation is not only that 
the mucociliary-clearance apparatus is composed 
of two polymer hydrogels but also that they 
compete for hydration. The force that mediates 
polymer-gel hydration — that is, the water-
drawing power — is described as the osmotic 
pressure of a hydrogel. Experimental measure-
ments revealed that the osmotic pressure of the 
normal mucus layer consisting of 2% solids is 
approximately 100 Pa,9,13 whereas the periciliary 
layer is more concentrated, with an osmotic 
pressure of approximately 500 Pa (Fig. 2B).13 The 
higher osmotic pressure of the periciliary layer 
in healthy persons ensures that it is well hydrated, 
providing appropriate lubrication for ciliary activ-
ity and transport of the overlying mucus layer.13
Integration of Epithelial Ion Transport  
and Mucus Hydration
The two-gel model allows for quantitative pre-
dictions with respect to interactions between 
Figure 2 (facing page). Two-Gel Model of Mucus Transport.
Panel A, left, shows the classic “gel-on-liquid” model show-
ing a mucus layer (MUC5AC and MUC5B) and a “sol” layer 
as liquid surrounding cilia. Panel A, right, shows the “two-
gel” model in which the mucus layer remains the same, 
but a periciliary layer (gel) is formed by tethered macro-
molecules, including MUC1, MUC4, and MUC16. Panel B 
shows epithelial ion and water transport in normal human 
airway epithelia. The percentage of solids in the normal 
mucus layer and osmotic pressures (π) of the normal mu-
cus layer (πML) and PCL (πPCL) in pascals (Pa) are noted. 
An ENaC in the apical membrane mediates sodium and 
liquid absorption.21 In parallel, the epithelium secretes 
chloride and bicarbonate anions through CFTR and calcium-
activated chloride channels (CaCC).21 The balance between 
active sodium absorption and secretion of chloride and bi-
carbonate anions, and hence fluid flow, is regulated in part 
by lumenal concentrations of extracellular ATP, interacting 
through P2Y2 receptors, and adenosine (ADO), interacting 
through A2b receptors.22 Panel C describes the relative water-
drawing powers of the mucus layer (πML) and PCL (πPCL) 
interfaced to epithelial cell–mediated fluid absorption or 
secretion (blue arrows). The length of the Hookean springs 
(to the right of the blue arrows) denotes the height of the 
PCL (purple) or mucus layer (green), and the spring diameter 
is inversely proportional to osmotic pressure. In a normal 
state (left), πML is lower than πPCL, represented by a green 
spring (πML) with a diameter larger than the purple spring 
(πPCL). In a dehydrated state (right), persistent or abnormal 
absorption initially removes fluid from the lower-osmotic-
pressure mucus layer but ultimately coordinately removes 
fluid from both the mucus layer and the PCL. The osmotic 
pressures of both layers are increased and equalized (small-
er spring diameters) and volume depleted (springs short-
ened). This state osmotically compresses the cilia and pro-
duces mucus stasis. Panel D shows the relationship between 
mucus concentration (i.e., percent solids) and osmotic 
pressure (Pa).9 Samples of mucus from healthy persons, 
sputum from patients with cystic fibrosis, and mucus ob-
tained from excised lungs of patients with cystic fibrosis 
are shown. Osmotic pressures in the mucus layer that are 
higher than the basal osmotic pressure of the PCL (black 
dashed line) are predicted to produce collapse of the PCL 
and slow MCC.13 Panel E shows MCC as a function of 
mucus-layer concentration predicted from the ratio of πML 
to πPCL. At normal mucus hydration (2% solids and 98% 
water), πML is below basal πPCL values, the PCL is well 
hydrated, and mucus transport is efficient. With modest 
mucus dehydration (3 to 4% solids and 96 to 97% water), 
πML slightly exceeds πPCL, modest compression of the 
PCL results, and MCC slows. When mucus dehydration is 
severe (7 to 10% solids and 90 to 93% water), the mucus 
layer osmotically compresses cilia, producing mucus stasis. 
Panel F shows interactions of airflow with mucus biophysical 
properties relevant to cough efficiency. In more distal air-
ways (below bifurcation), reduced airflows (smaller arrows) 
can only slide mucus along airway surfaces, a movement 
limited by friction between mucus and cell surfaces. At air-
way bifurcations, mucus remodels as it enters the proximal 
airway, which has a reduced aggregate surface area, a pro-
cess limited by mucus viscosity.11 In large airways (e.g., the 
trachea), the higher airflow (larger arrow) fractures intra-
mucus cohesive forces, adhesive forces between mucus 
and the cell surface, or both to expel mucus as sputum.23
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Figure 3. Muco-Inflammatory Positive-Feedback (“Vicious”) Cycles in Muco-Obstructive Disease.
Panel A shows the basal muco-obstructive disease state in which surface hydration and mucus concentration may be 
relatively normal but vulnerable to muco-obstruction with insults (e.g., aspiration or viral infection). Panel B shows 
insult-triggered formation of abnormal mucus plaque. Insults increase mucin secretion not accompanied by adequate 
hydration owing to abnormal fluid-secretory responses. Hyperconcentrated mucus activates resident macrophages 
(pink) and produces hypoxia in subjacent airway epithelia (blue). Panel C shows the generation of persistent, muco-
inflammatory positive-feedback cycles. Activated resident macrophages release interleukin-1β (left), and hypoxic 
necrotic epithelia (blue) release interleukin-1α (right). Interleukin-1α and -1β activate epithelial interleukin-1 receptors 
(IL1R1) to induce mucin biosynthesis mediated by SPDEF and ERN2 and expression of proinflammatory cytokines 
and chemokines (e.g., IL8 and CXCL1). Accelerated mucin secretion without proper hydration worsens mucus hyper-
concentration on airway surfaces and stimulates hypoxic macrophages and epithelia to release additional interleukin-
1α and -1β in positive-feedback loops (denoted by a plus sign). Secretion of proinflammatory mediators induces 
parallel neutrophil-mediated inflammation; parallel neutrophil-mediated, protease-induced mucin secretion; and other 
positive-feedback cycles (not shown). PO2 denotes partial pressure of oxygen.
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mucus-layer concentration (hydration) and the 
efficiency of mucociliary transport. These pre-
dictions are best understood from analyses of 
how the mucus and periciliary layers respond 
to f luid transport by the underlying airway epi-
thelium.
In healthy persons, airway epithelia can se-
crete or absorb ions and water and probably do 
both simultaneously.21 Maintenance of normal 
airway-surface hydration is provided by cilial 
mechanosensing of mucus-layer concentration, 
regulated release of ATP by ciliated cells onto 
the airway surface, and fine-tuning of ion-trans-
port and fluid-transport rates through purino-
ceptor activation (Fig. 2B).8,24 In the well-hydrated 
normal state (2% solids and 98% water), the 
mucus layer acts as a fluid buffer to ensure ef-
ficient mucus transport (Fig. 2C; and Fig. S1 in 
the Supplementary Appendix, available with the 
text of this article at NEJM.org). However, in 
muco-obstructive disease, abnormal epithelial 
fluid absorption depletes the airway surface of 
fluid, increases mucus concentrations, and raises 
osmotic pressures in the mucus layer to levels 
exceeding those in the periciliary layer (Fig. 2C). 
Moderately hyperconcentrated mucus that is as-
sociated with disease compresses cilia and slows 
mucus transport, whereas severe hyperconcen-
tration flattens cilia and produces mucus stasis 
and adhesion. Thus, the two-gel formulation 
predicts mucociliary transport rates from mucus 
concentrations (Fig. 2D and 2E) and explains 
why relatively small changes in hydration status 
(2% vs. 8% solids [i.e., 98% vs. 92% water]) pro-
duce disease.
Cough — Backup Mechanism Recruited  
to Clear Adherent Mucus
When cilial-dependent mucus clearance fails, 
cough becomes the backup clearance mecha-
nism.23 It is the combined failure of cilial- 
dependent and cough-dependent clearance that 
produces muco-obstructive disease. Like cilial-
dependent mucus transport, mucus concentra-
tion is a key determinant for all mucus proper-
ties associated with cough-dependent transport, 
including friction, viscosity, cohesion, and adhe-
sion (Fig. 2F, and Fig. S2 in the Supplementary 
Appendix).11
Patho genesis  
of Muco - Obs truc tion
An important feature of muco-obstructive lung 
diseases is disease heterogeneity — that is, there 
are regions of the lung that are normal and 
other regions within the same lung that are se-
verely diseased. Bronchiectasis is often a promi-
nent finding in computed tomography (CT) of 
the lung. However, a common feature that uni-
fies muco-obstructive diseases is the early mani-
festation of disease in small airways (bronchioles), 
as evidenced by pathological examination, micro-
computed tomography, and pulmonary-function 
studies.
The airways are defended against infection 
both by mechanical (mucus) clearance and by 
antimicrobial proteins and peptides that are se-
creted into mucus by airway epithelial cells.25,26 
The ability of antimicrobial molecules and anti-
bodies to suppress bacterial-infection replication 
is short lived, probably on the order of hours.26 
Consequently, a kinetic “horse race” is manifest 
in the lung, pitting the rate of acquisition of 
bacterial resistance to endogenous antimicrobial 
suppression against the rate of mechanical (mu-
cus) bacterial clearance. However, slowing of 
clearance alone is probably not sufficient to 
produce disease. It appears that the mucus layer 
needs to come to a stop, with the formation of 
mucus plaques and plugs within airway lumens, 
to produce muco-obstructive disease. Studies in 
animal models have shown that the full spec-
trum of muco-obstructive diseases, including air-
flow obstruction, inflammation, and intermittent 
infection, are observed with mucus concentra-
tion–dependent formation of plaques and plugs 
but not isolated defects in mucociliary clearance.27
Mucus plaque or plug formation in the air-
ways reflects an increase in mucin secretion, 
often stimulated by viral infections or aspira-
tion, coupled with poor epithelial hydration of 
newly secreted mucins (Fig. 3A and 3B). On 
formation of hyperconcentrated, static mucus 
plaques, a bistable positive-feedback (“vicious”) 
muco-inflammatory cycle is initiated (Fig. 3C).28,29 
Ultimately, severe or persistent muco-obstruc-
tion, typically associated with elevated airway 
levels of neutrophil elastase, drives the progres-
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sion from bronchitic to bronchiectatic or bron-
chiolectatic lesions typical of these diseases.30,31
Bacterial infection is a common feature of 
muco-obstructive lung diseases.2-4,32 Data from 
patients with cystic fibrosis or other muco- 
obstructive diseases indicate that the major sites 
of infection in muco-obstructive lung diseases 
are intralumenal mucus plaques and plugs, not 
airway epithelial-cell surfaces.32 The limitation 
of oxygen diffusion through mucus plaques to 
underlying actively metabolizing epithelial cells 
produces regions of hypoxia within mucus 
plaques (Fig. 3).32,33 Analyses of microbiome data 
from patients with cystic fibrosis or COPD have 
identified oral anaerobes as the first bacterial 
pathogens in the muco-obstructed lung.34,35 These 
data suggest that a mouth–lung aspiration axis, 
in which oral anaerobes infect hypoxic mucus 
plaques, may be a unifying concept for early 
bacterial infection in most muco-obstructive dis-
eases.35,36 Anaerobic bacteria can modify the 
hypoxic mucus environment to promote invasion 
by classic pathogens (e.g., Pseudomonas aeruginosa), 
which respond to mucus concentration–depen-
dent tightening of mucus meshes to grow as 
aggregates or biofilms.4,32,33,37,38 Future studies 
are required to establish whether oral pharyn-
geal f lora in sputum samples obtained from 
patients with muco-obstructive disease may, like 
classic pathogens, require treatment.
E x acer b ations
Exacerbations are typical of muco-obstructive 
diseases. An exacerbation is broadly defined as 
a change in the patient’s perception of well-
being, the seeking of health care, or a health 
care–implemented change in the patient’s medi-
cal regimen.39 In all muco-obstructive lung dis-
eases, the overall rate of progression of disease 
severity (e.g., loss of lung function) is probably 
heavily influenced by the incidence and severity 
of acute exacerbations. Common to all muco-
obstructive diseases, previous rates of exacer-
bation and gastric aspiration are predictors of 
future rates of exacerbation — that is, a patient 
with many past exacerbations is more likely to 
have future exacerbations than a patient without 
such a history.1
It is important to note that an exacerbation is 
superimposed on preexisting, heterogeneous 
muco-obstructive lung disease. Previous studies 
suggest that some exacerbations are caused by 
an intensification of disease in areas with pre-
existing disease, perhaps reflecting a change in 
bacteria through genetic drift or phenotypic re-
sponses to a local environment.40,41 However, the 
new physical findings that are associated with 
exacerbations suggest that many exacerbations 
are associated with the spread of disease to pre-
viously unaffected regions (Fig. S3 in the Supple-
mentary Appendix).42 A common mechanism for 
spread may be gastric aspiration; this concept is 
consistent with data from patients with COPD, 
non–cystic fibrosis bronchiectasis, or cystic fi-
brosis.43,44 Perhaps the major trigger for spread 
is viruses aspirated from upper airways into the 
lung. A spread mechanism is consistent with 
data from patients with cystic fibrosis or non–
cystic fibrosis bronchiectasis showing that the 
microbiome changes little during exacerba-
tions.34,45 Clinically, exacerbations must be treat-
ed vigorously to limit permanent loss of lung 
function.
Dise a se-Specific Path wa ys  
t o H y perconcen tr ation  
of A irwa y Mucus
Cystic Fibrosis
Cystic fibrosis is the most extensively studied 
disease with respect to the two-gel hypothesis 
describing mucus concentration–dependent dis-
ease. The abnormal concentration of mucus in 
the lungs of patients with cystic fibrosis reflects 
a primary abnormality of airway epithelial ion 
transport.4 In this disease, the airway epithelium 
is vulnerable to fluid hyperabsorption because of 
a defect in the secretion of chloride and bicar-
bonate anions mediated by the cystic fibrosis 
transmembrane conductance regulator (CFTR) and 
by an intact sodium absorptive path. Laboratory 
evidence suggests that cystic fibrosis can be trig-
gered by viral infections that lead to unre-
strained liquid absorption, mucus hyperconcen-
tration, and the formation of mucus plaques and 
plugs (Fig. S4 in the Supplementary Appendix).22
Mucus hyperconcentration as a feature of 
cystic fibrosis was first documented in adults. 
Sputum measurements revealed higher total 
mucin concentrations (Fig. 1C) and a higher 
percentage of solids (Fig. S4 in the Supplemen-
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tary Appendix) in patients with cystic fibrosis 
than in healthy persons.9 Sputum osmotic pres-
sures in healthy persons (approximately 100 Pa) 
were below the osmotic pressure of the peri-
ciliary layer (500 Pa), as predicted,13 whereas 
expectorated sputum samples from patients 
with cystic fibrosis had osmotic pressures slightly 
above basal periciliary-layer values (≥500 Pa) 
(Fig. 2D). The mucus extracted from the lungs of 
patients with cystic fibrosis at transplantation 
had even higher concentrations (10 to 15% solids) 
and osmotic pressures (>1000 Pa), findings con-
sistent with a failure to clear (cough out) highly 
concentrated, adherent mucus.9,11 Optical coher-
ence tomography of the upper airways in vivo of 
adults with cystic fibrosis revealed evidence of 
mucus hyperconcentration, slowed mucociliary 
clearance, and, as predicted by the two-gel hy-
pothesis, a reduction in the height of the peri-
ciliary layer.46
Recent data regarding bronchoalveolar lavage 
from children with cystic fibrosis in the Austra-
lian Respiratory Early Surveillance Team for 
Cystic Fibrosis (AREST CF) cohort showed that a 
persistent increase in mucin concentration and 
inflammatory cells preceded bacterial infection 
in the lung.47 “Rough” (hyperconcentrated) MUC5B 
and MUC5AC mucus flakes, probably of small-
airway origin, were also a feature of bronchoal-
veolar fluid from children with cystic fibrosis.48 
Although failure of CFTR-dependent bicarbonate 
secretion might suggest a role for pH in early 
cystic fibrosis, transbronchoscopic measurements 
in the AREST CF cohort did not detect a signifi-
cant difference in lower-airway pH between pa-
tients with cystic fibrosis and disease controls 
without cystic fibrosis. In addition, pH has less 
effect than concentration on the biophysical 
properties of mucus related to clearance or 
plaque formation.11 Aspirated oral anaerobes ap-
pear to be the first bacterial pathogens in the 
lungs of patients with cystic fibrosis, followed 
by the classic gram-negative pathogens that 
probably accelerate the vicious cycle depicted in 
Figure 3 and loss of lung function.4,49,50
COPD
COPD manifests as persistent airf low obstruc-
tion, most often in response to inhaled environ-
mental agents.1,51 Hyperconcentrated mucus has 
been reported in lower-airway samples obtained 
from patients with COPD, and higher mucus 
concentrations are correlated with reduced in 
vivo rates of mucociliary clearance.16 Data from 
a large cohort study involving patients with 
COPD suggest that a major trigger of COPD, 
cigarette smoke, is associated with an increase 
in mucin concentration.10 Furthermore, hyper-
concentration of mucins in sputum was associ-
ated in this cohort with disease severity, as in-
dexed by associations between increased mucin 
concentrations and greater airflow obstruction 
and higher exacerbation rates.10 Increased mucin 
concentrations were also associated with a sub-
group of patients with early COPD (i.e., those 
with nearly normal lung function), who were 
shown to be at risk for rapid progression of their 
disease.10
The airway epithelial defects that produce 
mucus hyperconcentration in COPD are com-
plex.51 Exposure to cigarette smoke may produce 
abnormalities in CFTR-mediated secretion of 
chloride anions through oxidant-induced reduc-
tion of CFTR transcription rates and direct dam-
age to CFTR protein in the apical membrane.52,53 
Furthermore, increased extracellular nucleotide 
and nucleoside metabolism decreases extracellu-
lar ATP and adenosine levels, which suggests de-
fective purinoceptor regulation of airway-surface 
hydration.16 These defects in epithelial ion and 
fluid transport (hydration) are amplified by ciga-
rette smoke–induced hypersecretion of MUC5AC 
and MUC5B.6 Mucin hypersecretion may be par-
ticularly important in COPD because accelerated 
metabolism of co-released adenosine diphosphate, 
adenosine monophosphate, and adenosine, cou-
pled with defective CFTR function, may limit 
paracrine adenosine–CFTR hydration responses 
that accompany mucin secretion.54
The mucin hyperconcentration that charac-
terizes patients with COPD is perhaps the mild-
est example in the muco-obstructive disease 
grouping (Fig. 1C). Patients with COPD also tend 
to have the least severe muco-obstructive airway 
disease, particularly with respect to the lower 
incidence of bronchiectasis and pseudomonas 
infection (Fig. 2B).55,56
Primary Ciliary Dyskinesia
The pathogenesis of primary ciliary dyskinesia 
has typically been considered as solely a “motor 
problem” caused by genetic abnormalities in 
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cilial shaft proteins, cilial beat frequency, and 
defective mucociliary clearance.3,57 However, 
sputum obtained from patients with primary 
ciliary dyskinesia also is abnormally hypercon-
centrated, which suggests that a “second hit” 
contributes to the pathogenesis of the disease 
(Fig. 1C).58 Studies that identified the mechano-
transduction pathways linking mucus concen-
tration with cilial strain–induced ATP release 
also showed that this signaling pathway was 
defective in patients with primary ciliary dyski-
nesia.24 This defect in ciliary sensing probably 
reduces the release of ATP onto airway surfaces, 
thereby decreasing fluid secretion and generat-
ing a hyperconcentrated mucus plaque or plug 
component to airflow obstruction.
The pulmonary phenotype of patients with 
primary ciliary dyskinesia, aside from the more 
basilar distribution of bronchiolectasis and bron-
chiectasis, is similar to that of cystic fibrosis but 
is shifted toward older ages with respect to dis-
ease severity–age relationships.3,59 Notable simi-
larities to cystic fibrosis include the presence of 
anaerobes in early primary ciliary dyskinesia, the 
subsequent acquisition of classic muco-obstruc-
tive or bronchiectatic pathogens (e.g., staphylo-
coccus, Haemophilus inf luenzae, and P. aeruginosa), 
and severe neutrophilic inflammation in the air-
ways with raised DNA concentrations.3 It is not 
clear whether the milder disease phenotype of 
patients with primary ciliary dyskinesia reflects 
the retention of partial ciliary activity in many 
genotypes of the disease, the persistence of 
CFTR functions other than hydration in primary 
ciliary dyskinesia, or other factors.
Non–Cystic Fibrosis Bronchiectasis
Non–cystic fibrosis bronchiectasis is a phenotype 
defined by bronchiectasis in the absence of a 
monogenetic cause.60 Although non–cystic fibrosis 
bronchiectasis is now typically defined by dilated 
bronchi on CT, classic pathological studies have 
highlighted severe small-airway disease, includ-
ing bronchiolectasis, mucus plugging, and in-
flammation, in this syndrome.61 Consistent with 
these pathological findings, non–cystic fibrosis 
bronchiectasis has the typical small-airway air-
flow impairment of muco-obstructive diseases.62
Non–cystic fibrosis bronchiectasis probably 
reflects an interaction between environmental 
stresses and genetic host-defense risk alleles, 
with bronchiectasis as a final common path-
way.60 Genetic studies suggest that non–cystic 
fibrosis bronchiectasis is associated with a spec-
trum of genetic risks, including abnormal muco-
sal host defense, immune function, or connec-
tive tissue.60 The recent reports that sputum 
obtained from patients with non–cystic fibrosis 
bronchiectasis is hyperconcentrated suggest that 
an epithelial defect in the regulation of mucin 
hydration may contribute to disease pathogene-
sis (Fig. 1C). Currently, genetic studies have not 
linked ion-transport genes to non–cystic fibrosis 
bronchiectasis, and direct measurements have 
suggested that CFTR functions normally in pa-
tients with non–cystic fibrosis bronchiectasis 
without CFTR mutations.63
The microbiome of patients with non–cystic 
fibrosis bronchiectasis is typical of muco-obstruc-
tive diseases, characterized by polymicrobial oral 
anaerobic bacteria, staphylococcus, and H. inf lu-
enzae, with approximately 15 to 20% of patients 
positive for P. aeruginosa.45,64 In this context, non–
cystic fibrosis bronchiectasis resembles early cys-
tic fibrosis.50 Patients with non–cystic fibrosis 
bronchiectasis have an incidence of nontubercu-
lous mycobacteria infection that may be as much 
as 60% higher than the incidence among pa-
tients with other muco-obstructive diseases; this 
finding indicates a potential role of immune-
deficiency alleles in non–cystic fibrosis bronchi-
ectasis.60,65
Di agnosis
Disease-specific criteria assist in the diagnosis 
of each muco-obstructive lung disease: for cystic 
fibrosis, levels of chloride anions in sweat and 
genetic testing66; for COPD, exposure history 
and spirometry1; for primary ciliary dyskinesia, 
nasal nitric-oxide measurements, cilia waveform 
analyses, and genetic testing3,57; and for non–
cystic fibrosis bronchiectasis, CT scanning.60 
The tools to make a general diagnosis of muco-
obstructive disease are also available. Patient-
related outcomes regarding the presence of 
cough, sputum production, and exacerbation fre-
quency can be obtained from general respiratory 
questionnaires.5 Measures of sputum inflamma-
tory cells and cytokines or chemokines aid in 
establishing the inflammatory component of 
airway muco-obstruction.
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Measures of mucus concentration (percent 
solids) and total mucin concentrations have also 
been explored as diagnostic tools.10 For example, 
mucin concentrations in sputum are signifi-
cantly associated with chronic bronchitis symp-
toms defined by patient-related outcome data, 
and receiver-operating-characteristic curve analy-
ses suggest that mucin concentration is a good 
biomarker for COPD.10
Ther a pies for Muco - Obs truc ti v e 
Dise a ses
Disease-specific therapies for one muco-obstruc-
tive disease, cystic fibrosis, are now available. 
Ivacaftor (VX-770) is a potentiator of residual 
CFTR function that has been approved for pa-
tients with cystic fibrosis with gating and some 
splicing CFTR mutations.67 Ivacaftor provided a 
model for the development of therapies for muco-
obstruction, as evidenced by impressive associa-
tions between improved airway-surface hydration 
in vitro, peripheral and central mucociliary clear-
ance in vivo, and clinically relevant outcomes 
(e.g., forced expiratory volume in 1 second [FEV1]). 
For patients with cystic fibrosis who are homo-
zygous for a deletion of phenylalanine 508 
(F508del) in CFTR, ivacaftor–lumacaftor and 
tezacaftor–ivacaftor are available but offer more 
modest clinical benefit. Three-drug combinations 
of correctors and potentiators await approval but 
appear to be highly effective in patients with at 
least one F508del mutation (approximately 90% 
of patients).
Hydrators
Perhaps the most direct approach in the treat-
ment of muco-obstructive lung diseases is to 
reduce the concentration of pathologic mucus 
— that is, rehydrate it. The currently available 
approach to achieve this goal is inhalation of 
osmotically active aerosols (e.g., hypertonic saline 
or mannitol).68,69 In clinical development are 
modulators of ion transport that may redirect 
airway epithelial ion transport from net absorp-
tive to secretory directions, providing a mecha-
nism for epithelial restoration of airway-surface 
hydration.70
Hypertonic saline is the most widely tested 
inhaled osmotic agent in muco-obstructive lung 
diseases. The use of hypertonic saline is best 
described in cystic fibrosis, producing sustained 
increases in mucociliary clearance, increased FEV1, 
and reduced frequencies of exacerbation.69,71 
Inhalation of hypertonic saline is often used in 
patients with non–cystic fibrosis bronchiectasis 
or primary ciliary dyskinesia, with some early 
evidence of efficacy,72 whereas inhalation of hy-
pertonic saline appears to be safe in sputum 
induction in patients with COPD but is untested 
as yet therapeutically.73
Mucolytics
Two recent observations suggest that attacking 
abnormal mesh and gel properties of mucus in 
addition to reducing concentration may be thera-
peutic. First, mucus viscosity is a key variable 
governing the mucus cohesive and adhesive prop-
erties relevant to cough efficiency, and reduc-
tions in viscosity with mucin S–S bond–reducing 
or surfactant agents decrease mucus adhesion 
and cohesion independent of concentration.11 
Second, the mucus plaques or f lakes that are 
recovered from young patients with cystic fibro-
sis during bronchoalveolar lavage are unable to 
swell and dissolve in excess solvent47 (i.e., they 
are “permanent” gels). Permanency can be con-
ferred by the generation of bonds with a long 
half-life between mucin polymers that can reflect 
oxidant-induced inter-mucin S–S bonds, inflam-
matory protein-mediated “sticker” interactions 
between adjacent mucins, or both.74 Thus, ther-
apies that are designed to reduce inter-mucin 
S–S bonds or block mucin–sticker interactions 
(e.g., with surfactants or glycopolymers) are be-
ing developed to improve both mucus swelling 
and cough clearance.8,75 Inhaled acetylcysteine has 
not proved to have the mucin-reductive activity 
required for a therapeutic effect.8 (Additional 
references for this article are listed in the Sup-
plementary Appendix.)
Conclusions
Muco-obstructive diseases are characterized 
by mucus hyperconcentration. The four muco- 
obstructive diseases differ with respect to the 
epithelial abnormalities that produce mucus hyper-
concentration but follow a final common path 
of mucus concentration–dependent formation 
of mucus plaques and plugs. Adherent mucus 
plaques may stimulate a positive-feedback muco-
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inflammatory cycle that renders mucus plaques 
permanent and damaging to airway walls. Thera-
pies that are designed to rehydrate and restore 
mucous viscous or elastic properties are rational. 
The challenge is to deliver these therapies to the 
small airways, where mucus obstruction may be 
complete and the physics of aerosol-deposition 
efficiency may be poor. However, the concept that 
these diseases may be highly treatable emanates 
from studies involving patients with cystic fibro-
sis in whom potentiators have reversed mucus 
obstruction in both large and small airways.67
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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